RSV MAT

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Respiratory Syncytial Virus Infections

Phase 3

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

TerminatedNCT04605159

GlaxoSmithKlineRespiratory Syncytial Virus Infections

Start: 2020-11-20End: 2023-06-14Updated: 2025-02-20

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

TerminatedNCT04980391

GlaxoSmithKlineRespiratory Syncytial Virus Infections

Start: 2021-08-03End: 2023-05-30Updated: 2025-04-20

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

WithdrawnNCT05229068

GlaxoSmithKlineRespiratory Syncytial Virus Infections

Start: 2022-03-11End: 2024-10-24Updated: 2022-04-07

Related Papers

Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants.

2026-03-01

Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine

Clinical Infectious Diseases2025-01-295 citations

RSV Prefusion F Protein–Based Maternal Vaccine — Preterm Birth and Other Outcomes

New England Journal of Medicine2024-03-13109 citations

Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children

Journal of the Pediatric Infectious Diseases Society2023-05-0114 citations

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial

The Journal of Infectious Diseases2023-02-0158 citations